On Monday, Relmada Therapeutics Inc (NASDAQ: RLMD) opened lower -6.40% from the last session, before settling in for the closing price of $0.47. Price fluctuations for RLMD have ranged from $0.34 to $7.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 16.46% at the time writing. With a float of $25.28 million, this company’s outstanding shares have now reached $30.17 million.
The firm has a total of 20 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Relmada Therapeutics Inc is 16.22%, while institutional ownership is 41.26%. The most recent insider transaction that took place on Sep 11 ’24, was worth 153,707. In this transaction Chief Executive Officer of this company bought 51,407 shares at a rate of $2.99, taking the stock ownership to the 384,024 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Chief Executive Officer bought 55,579 for $2.71, making the entire transaction worth $150,619. This insider now owns 299,603 shares in total.
Relmada Therapeutics Inc (RLMD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.46% per share during the next fiscal year.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Check out the current performance indicators for Relmada Therapeutics Inc (RLMD). In the past quarter, the stock posted a quick ratio of 6.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.87, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Analysing the last 5-days average volume posted by the [Relmada Therapeutics Inc, RLMD], we can find that recorded value of 1.98 million was better than the volume posted last year of 1.37 million. As of the previous 9 days, the stock’s Stochastic %D was 58.27%. Additionally, its Average True Range was 0.13.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 2.70%, which indicates a significant decrease from 51.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.83% in the past 14 days, which was lower than the 254.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9737, while its 200-day Moving Average is $3.1049. Now, the first resistance to watch is $0.4635. This is followed by the second major resistance level at $0.4869. The third major resistance level sits at $0.4987. If the price goes on to break the first support level at $0.4283, it is likely to go to the next support level at $0.4165. Now, if the price goes above the second support level, the third support stands at $0.3931.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
There are currently 30,174K shares outstanding in the company with a market cap of 13.28 million. Presently, the company’s annual sales total 0 K according to its annual income of -98,790 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,730 K.
